Antidiabetics Market Set to Register 10.5% CAGR During 2017-2024

The Antidiabetics market dynamics, forces, companies and trends have been determined after conducting a detailed study of the industry for this newly released research report now available with Market Study Report.
Antidiabetics Market is set to reach USD 110 billion by 2024; according to a new research report. Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
Increasing number of obese and diabetic patients coupled with rising patient awareness levels serve as high impact rendering factors for antidiabetic market growth over the forecast period.
Rising geriatric population base, innovation of new drugs, increasing adoption of drugs and increased disposable income should further drive industry growth. Owing to the changes in lifestyle, even children between age group of 13-14 years are at high risk to get diabetes. It offers huge opportunities industry players.
Favorable government initiatives such as Diabetes Prevention Program (DPP) that aims to help individuals with prediabetes, reduces their risk to develop type 2 diabetes. Trained lifestyle coach works with participants and communicate lifestyle skills, such as, eating healthy food, physical activity and managing stress. Such initiatives should propel industry growth over the forecast period.
Advent of new technologies in products like long acting insulin analogs as well as rapid acting with increased effectiveness should drive industry growth over the forecast timeframe. The novel insulin pen technology permits low-pain and suitable daily insulin injection that should upsurge therapy sales. Type 2 diabetes mellitus (T2DM) has strong familial aggregation, the person with a parent or sibling with disease are at high risk. People with obesity, hypertension, or dyslipidemia and women with history of gestational diabetes are also at high risk to develop T2DM.
Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/467744/
U.S. antidiabetics market valued over USD 19.4 billion in 2016 and expected to grow significantly over the coming years. Increased healthcare expenditure along with availability of improved healthcare infrastructure and favorable reimbursement policies should drive antidiabetics market .
UK contributed for significant revenue share in 2016. The growth is attributed due to wide range of funds offered by Diabetes UK for research related to the treatment of diabetes and its complications. In November 2016, the Prime Minister introduced new Diabetes UK office on World Diabetes Day.
Japan antidiabetics market should grow at significant rate over the forecast period. Diabetic population is on rise due to lifestyle changes that will accompany economic growth and drive antidiabetic market growth. The Japan Diabetes Society (JDS) encourage progress and development of diabetes study and prevent people from disease in the country.
Brazil contributed for significant revenue share. The growth is attributed due to early adoption of insulin analogues and increased use of these products in the country.
Some of the companies operating in antidiabetics market include Eli Lilly, Pfizer, Novo Nordisk, Takeda Pharmaceuticals, Sanofi Aventis, Merck, Boehringer Ingelheim and Oramed Pharmaceuticals.
Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/467744/
Table of Content:
Chapter 1. Methodology
1.1. Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Market definition and forecast parameters
1.2. Data sources
1.2.1. Secondary
1.2.2. Primary
Chapter 2.Executive Summary
2.1. Antidiabetics industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Application trends
2.1.4. Regional trends
Chapter 3. Antidiabetics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact force
3.3.1. Growth drivers
3.3.1.1. Gradual increase in prevalence of diabetes
3.3.1.2. Presence of strong product pipeline portfolio
3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity
3.3.2. Industry pitfalls & challenges
3.3.2.1. High insulin prices
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By application
3.5. Regulatory landscape
3.5.1. U.S
3.5.2. Europe
3.6. Reimbursement scenari
3.6.1. U.S
3.6.2. Europe
3.7. Pipeline overview
3.8. Porter's analysis
3.9. Competitive landscape, 2016
3.9.1. Business overview
3.9.2. Revenue analysis
3.9.3. Product landscape
3.9.4. Strategy dashboard
3.10. PESTEL analysis
Chapter 4. Antidiabetics Market, By Product
4.1. Global antidiabetics market share, by product, 2016 & 202
4.2. Insulin
4.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
4.2.2. Rapid acting analog
4.2.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
4.2.3. Long acting analog
For More Info: http://www.openpr.com/news/archive/144590/marketstudyreport-com.html
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
Contact Us:
Market Study Report
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: [email protected]
Web site: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog/